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Abstract
Background: This cross-sectional pilot study evaluates diagnostic accuracy of live colposcopy versus static image
Swede-score evaluation for detecting significant precancerous cervical lesions greater than, or equal to grade 2
severity (CIN2+).
Methods: VIA or HrHPV positive women were examined using a mobile colposcope, in a rural clinic in Kolkata,
India. Live versus static Swede-score colposcopy assessments were made independently. All assessments were by
gynecologists, junior or expert. Static image assessors were blinded to live scoring, patient information and final
histopathology result. Primary outcome was the ability to detect CIN2+ lesions verified by directed biopsies.
Diagnostic accuracy was calculated for live versus static Swede-score in detecting CIN2+ lesions, as well as for
interclass correlation.
Results: 495 images from 94 VIA positive women were evaluated in this study. Thirteen women (13.9%) had CIN2+
on biopsy. No significant difference was found in the detection of CIN2+ lesions between live and static assessors
(area under curve = 0.69 versus 0.71, p = 0.63). A Swede-score of 4+, had a sensitivity of 76.9% (95% CI 46.2–95.0%)
and 84.6% (95% CI 54.6–98.1%), for live- and static-image assessment respectively. The corresponding positive
predictive values were found to be 90.9% (95% CI 75.7–98.1%) and 92.6% (95% CI 75.7–99.1%). The interclass
correlation was good (kappa statistic = 0.60) for the senior static assessors.
Conclusions: Swede-score evaluation of static colposcopy images was found to reliably detect CIN2+ lesions in this
study. Larger studies are needed to further develop the colposcopy telemedicine concept which may offer reliable
guidance in management where direct specialist input is not available.
Trial registration: Ethical approval of the study was obtained by the Chittaranjan National Cancer Institute (CNCI)
Human Research Ethics Committee (4.311/27/2014). The trial was retrospectively registered in the Clinical Trails
Registry of India CTRI/2018/03/012470.
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Background
Today, cervical cancer is largely preventable through
regular screening, and countries with established cervical
screening programs have seen up to an 80% reduction in
the incidence of disease [1, 2]. Worldwide, almost 9 out
of 10 deaths from cervical cancer occur in low- and
middle-income countries (LMIC) [3]. This is largely due
to a lack of organised screening programs, shortage of
specially trained clinicians, as well as the high costs and
immobility of diagnostic equipment [4, 5]. The problem
is also present in European countries where there is a
lack of organised screening programs or reduced access
to screening services [1, 6].
The evolution of telecommunication technologies has
given rise to the field of telemedicine, which allows spe-
cialised input regardless of geographical location. While
not specific to cervical cancer screening, previous stud-
ies have found a positive association between telemedi-
cine and increased access to specialized care, decreased
costs to patient, reduced treatment costs at earlier stage
of disease, and overall increased socioeconomic returns
[7]. With increasing access to internet and mobile phone
connectivity, telemedicine offers potential solutions for
improving access and quality of cervical screening for
women in low-resource settings as well as those who
have reduced access to screening services due to geo-
graphical station [8–12].
Globally, cervical cancer screening and examination is
performed by nurses, midwives and colposcopy special-
ists with varying accuracy. Supervision and support by
senior clinicians is often difficult to obtain [4]. A single
visit approach using Visual Inspection with Acetic acid
(VIA) has been shown to have benefits in low-resource
settings [13–16]. This approach is recommended by the
World Health Organization (WHO) when there is no
other screening option, as it is the cheapest and most
feasible method of screening in some countries, ensuring
a strong connection between screening and treatment
[17]. However, these programs often lack quality con-
trols and the efficacy of screening may be further under-
mined by inter-observer variation due to subjectivity of
assessments and variable accuracy, all of which are in-
herent in visual assessments [4, 18, 19]. Telemedicine
has the potential to overcome the lack of on-site super-
vision [4], and increase the accuracy of assessments [11,
12]. Investigating the accuracy of static image colpos-
copy images by specialists is a fundamental step in de-
termining the feasibility of colposcopy telemedicine.
This pilot study evaluates the diagnostic accuracy of
live colposcopy Swede score evaluation versus static
image Swede score evaluation for detecting cervical
intra-epithelial neoplastic lesions greater than, or equal
to grade 2 severity (CIN2+). We investigate the differ-
ences in accuracy between live specialist assessment and
static image assessment using the Gynocular colposcope
and its mobile phone application.
Methods
This cross-sectional community-based study was con-
ducted in cervical screening camps, covering the rural
parts of West Bengal, in Kolkata, India, between April
2014 and April 2016 (Trial registration: CTRI/2018/03/
012470). Ethical approval of the study was obtained by
the Chittaranjan National Cancer Institute (CNCI) Hu-
man Research Ethics Committee (4.311/27/2014). Oral
and written consent was obtained before inclusion in the
study.
Non-pregnant, previously unscreened women between
30 and 60 years of age with uteri were eligible for the
study and invited to participate consecutively. All
women received both VIA (performed in accordance
with the WHO guidelines [20]) and high-risk oncogenic
human papillomavirus (HR-HPV) testing (Hybrid Cap-
ture 2, QIAGEN™, Gaithersburg, USA [21]). Those who
were either VIA or HR-HPV positive had a colposcopy
examination on-site by a senior clinician using the
Gynocular (Gynius AB, Stockholm, Sweden) [22]. The
Gynocular is a hand held, battery operated, monocular
colposcope with green light filter and optical zoom cap-
acity between 4-14X. A total of 94 screen-positive
women were recruited for the study. Standard colpo-
scopic examination was performed, including visualisa-
tion of the vagina, vulva and cervix following insertion
of a speculum, examination of cervical vessel patterns
using the red-free mode (or green filter), application of
5% acetic acid for 1 min and finally assessment following
application with Lugol’s iodine. The examination was
completed with at least one biopsy from the most severe
lesion. When no lesion was seen, a biopsy was taken
randomly from the squamocolumnar junction. The find-
ings of the live examination were documented using the
parameters of the Swede score, which includes measure-
ments for acetowhiteness, appearance of margins, ves-
sels, lesion size, and iodine staining (Table 1) [23]. Each
parameter is scored between zero and two. Treatment is
based on the summed total. A treatment threshold of 5
was used in this study [24].
Colposcopic images were captured thorough the
Gynocular colposcope using a Samsung Galaxy S3 mo-
bile (Samsung Electronics, Seoul, South Korea). The
Samsung S3 mobile includes an 8 megapixel camera
with a zoom function (Fig. 1). Up to six photographs
were used for each patient. Timing of the pictures, fol-
lowing these steps, was at the discretion of the colposco-
pist and not specified in the study protocol. All photos
were taken before biopsies were obtained. For each pa-
tient, there were no two pictures that were the same.
However, some steps of the colposcopy examination
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may not have been captured, and at some images were
similar, but using both low and high magnification. All
images pertaining to each patient were assessed to esti-
mate the Swede score.
Assessors included one live colposcopist, a senior
gynecology oncologist and six international colposco-
pists (four senior, two junior). The group of colposco-
pists were residing in India, Sweden, United Kingdom
and Switzerland. The static assessors each reviewed the
images from every participant. No additional clinical in-
formation was provided.
All women had one or more cervical biopsy evaluated
according to clinical routine. In cases where there was no
visible lesion, a random biopsy was taken from the squamo-
columnar junction and evaluated. Diagnostic accuracy was
calculated for live versus static Swede score impression in
detecting CIN2+ lesions. CIN2 is a well-established thresh-
old for treatment in cervical screening due to the increased
risk of progression from this stage and beyond [25]. This
was a pre-specified threshold and is widely accepted for the
assessment of diagnostic accuracy in cervical cancer screen-
ing studies [13, 20]. Interclass correlation was also assessed.
Table 1 Swede score and description of scoring [17]
Score 0 1 2 Total
Acetowhite uptake Nil or transparent Shady, milky (not transparent not opaque) Distinct, opague white
Margins surface Diffuse Sharp but Irregular, jagged,
“geographical” satellites
Sharp and even, difference
in surface level such as “cuffing”
Vessels Fine, regular Absent Coarse or atypical
Lesion size < 5 mm 5–15 or or 2 quadrants > 15mm or spanning
3–4 quadrants or
endocervically undefined
Iodine staining Brown Faintly or patchy yellow Distinct yellow
Total /10
Julie Bowring, Bjorn Strander, Martin Young, Heather Evans, Patrick Walker, The Swede Score: Evaluation of a Scoring System Designed to Improve the Predictive
Value of Colposcopy, Table 1, Journal of Lower Genital Tract Disease, vol 14, issue 4, pages 301–305
https://journals.lww.com/jlgtd/Abstract/2010/10000/The_Swede_Score__Evaluation_of_a_Scoring_System.5.aspx promotional and commercial use of the material
in print, digital or mobile device format is prohibited without the permission from the publisher Wolters Kluwer. Please contact permissions@lww.com for further
information. License to reprint Swede Score Model is included as an additional document to this paper (Additional file 1)
Fig. 1 Colposcopy telemedicine equipment. From left to right - Gynocular device, telemedicine smartphone based patient record system, clinical
examination and Swede score tool. Below - images obtained from the unit
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Statistics analysis
Descriptive statistical methods were used to report pa-
tient baseline demographic and clinical characteristics
using percentages and standard deviations (SD). Histo-
logical biopsy findings of CIN2+ was used as the refer-
ence standard in the study. We calculated test accuracy
(sensitivity, specificity, positive predictive value, and
negative predictive value) with corresponding 95% Con-
fidence Intervals (CIs) for live colposcopy Swede score
and corresponding static colposcopy Swede scores to de-
tect CIN 2+. The receiver operator curves (ROC) for
Swede scores were plotted as sensitivity against
1-specificity. To test reliability of the test and the level
of agreement between live and static image colposcopy
assessment, we calculated the percentage agreement and
the weighted kappa (ĸ) statistic [26]. The statistical soft-
ware used to analyse results was R version 3.2.5.
Results
In this study, 495 images from 94 VIA positive women
were evaluated. The average age of women was 37 years.
The incidence of CIN2+ was 13.8%, as expected in an
unscreened general population [10]. This was mostly de-
tectable by VIA (n = 12/13 CIN2+ lesions were VIA
positive, 92.3%). VIA alone was found to yield a high
false positive rate (86.2% n = 50/58). Of the VIA positive
women, 77% were HR-HPV negative (Table 2).
Accuracy was assessed using a histological reference
standard and the CIN classification described above. The
results show that the static-image, Swede score assessment
could correctly identify most CIN2+ lesions. In our study,
an improvement in test accuracy is seen using a threshold
of 4, where live versus static image assessment had a sen-
sitivity of 76.9% (95% CI 46.2–95.0%) and 84.6% (95% CI
54.6–98.1%), respectively. The corresponding positive pre-
dictive values were found to be 90.9% (95% CI 75.7–
98.1%) and 92.6% (95% CI 75.7–99.1%). Furthermore,
Table 3 shows that different thresholds can yield a
spectrum of accuracies. There were too few women with
CIN3+ on biopsy to perform the test accuracy analysis on
this severity of disease alone.
Our findings showed that using static images are at
least as good as live examination (Table 3) in colpo-
scopic assessment of the cervix. The equivalence of live
versus static examination was further illustrated in Figs. 2
and 3. There were no differences in the overall Area
Under the Curve (AUC) value for live versus static as-
sessments in detecting CIN2+ lesions (p = 0.63). The
median number of images per patient was 5 (range 3–6).
The majority of women (79.8%) had five or six images
obtained at live-colposcopy. With an increased number
of images to review, static image assessors were more ac-
curate with their assessments (review of 5 images was
associated with AUC = 0.690 and review of six images
was associated with AUC = 0.775). There were too few
positive biopsies in the groups of women who had three
or four images taken to perform this analysis.
We found good agreement between both static and
live assessors, measured by the weighted ĸ statistic (ĸ
statistic > 0.6) among senior consultants. Fig. 3 shows
the ROC for each colposcopist to detect CIN2 lesions by
Swede score. One live colposcopist (Brown line) and six
static image colposcopists (four of whom were expert
colposcopists; Red, blue, green purple lines) and two
junior (orange and yellow lines). The area under the
curve score for the live colposcopy, performed by a
gynecology oncologist, was 0.687. The AUC for the
static image colposcopists ranged between 0.64–0.72.
The results showed no difference in the detection of
CIN2+ lesions between live and static assessors (AUC =
0.69 and 0.71, p = 0.63). Two static image colposcopists
demonstrated even greater sensitivity than the expert
live colposcopist (0.70 and 0.73 compared to 0.69). The
two junior colposcopists achieved AUC of 0.57 and 0.59.
Fig. 2 shows the summed average of all static colposco-
pists compared to the live colposcopist.
Discussion
Our results found that CIN2+ lesions can be accurately
diagnosed through static images using the Swede score.
We also found that this method was as at least as effect-
ive as that achieved in a live assessment (AUC live = 0.69
and AUC static 0.71, p = 0.63).
A strength of the study is that cervical biopsy served
as the reference standard and was performed on every
patient. Biopsies were analyzed in a single site labora-
tory. A range of assessor experience was included in the
analysis, adding to the generalizability of our findings.
Assessments were standardized using the validated scor-
ing tool, the Swede score [23, 27]. However, a notable
limitation is that the quality of the monitors used to
view the images and the image size viewed were not
Table 2 Baseline findings
VIA+ HPV+
n = 10
VIA+ HPV-
n = 58
VIA- HPV+
n = 26
Total
n = 94
Age, mean (sd) 33.6 (2.9) 35.3 (5.9) 41.5 (7.9) 36.8 (6.9)
Biopsy (%)
Benign 4 (40.0) 37 (63.8) 21 (80.8) 62 (66.0)
CIN1 2 (20.0) 13 (22.4) 4 (15.4) 19 (20.2)
CIN2 2 (20.0) 5 (8.6) 1 (3.8) 8 (8.5)
CIN3 1 (10.0) 3 (5.2) 0 (0.0) 4 (4.3)
ICC 1 (10.0) 0 (0.0) 0 (0.0) 1 (1.1)
Legend: sd standard deviation, % percentage, VIA+ positive for visual
inspection with acetic acid, VIA negative for visual inspection with acetic acid,
HPV+ positive test for human papillomavirus, HPV negative test for human
papillomavirus, CIN1,2,3 Cervical intra-epithelial neoplastic lesions grade 1,2,3,
ICC invasive cervical cancer
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controlled for, which may have affected the assessment
made. Timing of image capture after the application of so-
lutions, and detailed instructions about the images to cap-
ture were not included and left to the discretion of the live
colposcopist. The number of images per patient was not
standardized which is considered a weakness of the study
and no adjustment was made in the analysis for autocor-
relation. Biopsies were taken of the worst lesion, although
multiple biopsies may have improved detection of CIN2+
lesions. We also elected to use a histologically proven
CIN2+ as the reference, because this has greater applica-
tion in the real-world setting. Using the histological refer-
ence of CIN3 may have resulted in improved test
accuracies and is also known to have better reproducibility
in colposcopic examination. In addition, inter-observer
variation is an inherent problem in colposcopy and is a
characteristic limitation of studies such as this. We used
Swede score in an effort to counteract the limitations of
inter-observer variation in colposcopy [28–30]. The sam-
ple size is moderate in relation to other studies performed
in this field, however, a larger sample size would give
greater integrity to the findings.
Literature on the application of telemedicine in colpos-
copy remains divided [31]. Previous landmark papers using
the ASCUC/LSIL triage study for cervical cancer (ALTS)
data questioned the accuracy of static images in detecting
borderline lesions [28, 29]. However, others have shown
that the development of smartphones (not yet developed at
the time of the above study) and static images can be a use-
ful adjunct to colposcopy [8, 12, 32–34]. Gauthier et al.
[12] performed a cross-sectional study using photographs
(taken with 13 megapixels, autofocus and 2X optical zoom)
as an adjunct to VIA and VILI. This study included 88
women, with one live colposcopist and four static colposco-
pists. They reported that live evaluation had a sensitivity of
28.6 (95% CI 3.7–71) whereas the best static evaluation had
a sensitivity of 85.7 (95% CI 42.1–99.6). In an effort to ad-
dress the issue of inter-observer variability, the live colpos-
copist also assessed the static images four months after the
original assessment, which increased the sensitivity to 71.4
(95% CI 29–96.3). Further, Liu et al. [32] evaluated the lar-
gest number of static colposcopy images, where 558
women were assessed by six live colposcopists and one
static image colposcopist. This study reported a 92% agree-
ment between live and static assessments (ĸ statistic = 0.39
95% CI 0.21–0.57) using colposcopic signs including aceto-
whitening. Analysis of the ALTS data showed only fair cor-
relation between evaluators (ĸ statistic 0.26, 95% CI 0.22–
Table 3 Sensitivity and specificity in detecting CIN2+ for Live and Static examinations
Swede Score Sensitivity Specificity PPV NPV
Live (95% CI) Live (95% CI) Live (95% CI) Live (95% CI)
Static (95% CI) Static (95% CI) Static (95% CI) Static (95% CI)
10 0.0% (0.0–24.7%) 98.8% (93.3–100.0%) 86.0% (77.3–92.3%) 0.0% (0.0–97.5%)
0.0% (0.0–24.7%) 100.0% (95.5–100.0%) 86.2% (77.5–92.4%) NaN% (0.0–100.0%)
9 15.4% (1.9–45.4%) 98.8% (93.3–100.0%) 87.9% (79.4–93.8%) 66.7% (9.4–99.2%)
0.0% (0.0–24.7%) 100.0% (95.5–100.0%) 86.2% (77.5–92.4%) NaN% (0.0–100.0%)
8 30.8% (9.1–61.4%) 97.5% (91.4–99.7%) 89.8% (81.5–95.2%) 66.7% (22.3–95.7%)
15.4% (1.9–45.4%) 95.1% (87.8–98.6%) 87.5% (78.7–93.6%) 33.3% (4.3–77.7%)
7 46.2% (19.2–74.9%) 88.9% (80.0–94.8%) 91.1% (82.6–96.4%) 40.0% (16.3–67.7%)
53.8% (25.1–80.8%) 87.7% (78.5–93.9%) 92.2% (83.8–97.1%) 41.2% (18.4–67.1%)
6 53.8% (25.1–80.8%) 77.8% (67.2–86.3%) 91.3% (82.0–96.7%) 28.0% (12.1–49.4%)
69.2% (38.6–90.9%) 67.9% (56.6–77.8%) 93.2% (83.5–98.1%) 25.7% (12.5–43.3%)
5 76.9% (46.2–95.0%) 39.5% (28.8–51.0%) 91.4% (76.9–98.2%) 16.9% (8.4–29.0%)
76.9% (46.2–95.0%) 45.7% (34.6–57.1%) 92.5% (79.6–98.4%) 18.5% (9.3–31.4%)
4 76.9% (46.2–95.0%) 37.0% (26.6–48.5%) 90.9% (75.7–98.1%) 16.4% (8.2–28.1%)
84.6% (54.6–98.1%) 30.9% (21.1–42.1%) 92.6% (75.7–99.1%) 16.4% (8.5–27.5%)
3 76.9% (46.2–95.0%) 37.0% (26.6–48.5%) 90.9% (75.7–98.1%) 16.4% (8.2–28.1%)
84.6% (54.6–98.1%) 13.6% (7.0–23.0%) 84.6% (54.6–98.1%) 13.6% (7.0–23.0%)
2 76.9% (46.2–95.0%) 33.3% (23.2–44.7%) 90.0% (73.5–97.9%) 15.6% (7.8–26.9%)
92.3% (64.0–99.8%) 8.6% (3.5–17.0%) 87.5% (47.3–99.7%) 14.0% (7.4–23.1%)
1 100.0% (75.3–100.0%) 2.5% (0.3–8.6%) 100.0% (15.8–100.0%) 14.1% (7.7–23.0%)
92.3% (64.0–99.8%) 2.5% (0.3–8.6%) 66.7% (9.4–99.2%) 13.2% (7.0–21.9%)
Legend: CI confidence intervals
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0.31). A subsequent analysis has also been performed with
full representation of cervical precancerous lesions, includ-
ing CIN2+ lesions, in which 112 images were assessed by
two colposcopists and a total of 939 images reviewed [29].
This study found that colposcopists agreed on the diagnosis
for only 56.8% of images and concluded that colposcopic
diagnosis using static images is poorly reproducible. There
were no details provided with regards to image-capturing
technology used in these earlier studies [12].
The reported improvement in the evaluation of static im-
ages between earlier and later studies may be associated with
the evolution of image-capturing technologies. Gauthier et
al. also attributed the significant difference in assessments to
the increased expertise of the static assessor [12]. Further-
more, assessment of static images has the advantage of
allowing more time to analyse and compare images in detail,
without compromising patient comfort, as well as the ability
to increase image size and repeated review of previous im-
ages. Improved detection may also result from high pixel
images which can be manipulated to zoom in on suspicious
regions and transformation zone comparisons can be made
immediately with the native cervix. Advances in imaging
technology during the decade separating the works de-
scribed above, as well as in the transfer and quality of im-
ages, impact the quality of interpretation of static images;
therefore older literature may be less relevant today.
The problem of inter-observer variation may be secondary
to colposcopists failing to identify characteristics of lesions
consistently when assessing lesion grade. All the studies de-
scribed above used different assessment criteria. Jermoimo
et al. and Massad used use a verified scoring system (the
Reid score) [28, 29] and the present study uses the Swede
score. The Swede score supersedes the older Reid’s index,
which excludes lesion size and scores acetowhiteness differ-
ently [23]. Using a scoring system ensures all features are
consistently assessed and may reduce inter-observer vari-
ability [23, 35]. A recent study examining the efficacy of
both Swede score and Reid’s score found that the sensitivity
and specificity of the two assessment tools was very high
(sensitivity: 100% vs 96.9%, specificity: 88.4% vs 95.3%, re-
spectively) [35]. These are both highly sensitive and specific
conditional upon the threshold used. Standardization of the
colposcopic examination also makes the practice more ac-
cessible and allows practitioners with differing educational
and clinical expertise to perform it with improved accuracy.
The performance of the scoring system in this study is lower
than that reported in the earlier literature [23, 35]. This may
be explained by sample size bias between studies.
It is often suggested that static images fail to show the
dynamic changes in response to uptake of acetic acid
[32], as acetowhitening has been found to have higher
replicability and correlation to severity of disease [36, 37].
Fig. 2 ROC curve and accuracy in detecting CIN2+ by Swede Score for live and static colposcopists. Bold line = test accuracy of each swede score
when live assessment made, Dashed line = test accuracy at each swede score when using static images (average of all assessors). Lighter lines
show the respective 95% confidence intervals. AUC = area under the curve
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Our study refutes this because no differences in overall
assessment of static versus live assessment was found.
Furthermore, advances in technology and imaging devices
may allow short videos to be used in place of static
images, which may further improve remote assessments.
Telemedicine offers the potential to improve cervical
screening in remote and low-resource settings. However,
there are two questions that require more robust investiga-
tion: 1) can diagnosis of CIN2+ lesions by static images yield
adequate test accuracy?, 2) is static image assessment com-
parable to live colposcopic assessment?. Our study suggests
colposcopy telemedicine may be a solution to a significant
global issue however, larger studies are needed to confirm
these findings.
Conclusions
Our cross-sectional pilot study indicates that CIN2+
lesions can be reliably detected by Swede score evalu-
ation of static colposcopy images. However, larger stud-
ies are needed to further develop the colposcopy
telemedicine concept. Telemedicine may offer reliable
guidance in the management of significant precancerous
cervical lesions in areas where direct specialist examin-
ation or input is not available. It is also useful for quality
control, which is often missing in low-resource settings
and of upmost importance in visually based screening
programs.
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